Welcome to our dedicated page for BIOLASE news (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on BIOLASE stock.
BIOLASE, Inc. (BIOL) generates frequent news as a medical device company focused on dental laser systems for dentistry and medicine. Company announcements describe BIOLASE as a global or globally recognized leader in dental laser technology, with principal products that include dental laser systems used for cosmetic and complex surgical procedures and related consumables such as disposable tips. News coverage often highlights how its laser platforms aim to provide less pain and faster recovery times for patients, while supporting a wide range of dental disciplines.
Investors and dental professionals following BIOLASE news will see updates on product launches, clinical education initiatives, financial performance, capital markets developments, and corporate restructuring events. Recent releases have covered the launch of the Waterlase iPlus Premier Edition all‑tissue laser system, featuring modular software design, enhanced user interface, on‑board animations, and Wi‑Fi‑enabled remote diagnostics. BIOLASE news also includes information on educational programs such as the “Let’s Talk Dental” webinar series and the Waterlase and Epic Diode academies, which address topics across restorative dentistry, periodontics, endodontics, pediatric dentistry, dental hygiene, and practice management.
Financial and corporate news items provide detail on quarterly and full‑year results, trends in laser and consumables revenue, gross margin, operating expenses, and the use of non‑GAAP measures such as Adjusted EBITDA. In 2024, BIOLASE announced its delisting from The Nasdaq Stock Market and subsequent trading on OTC Markets, as well as voluntary Chapter 11 proceedings and a proposed sale of substantially all assets to Sonendo Inc. For users tracking BIOL stock and BIOLASE developments, this news page offers a centralized view of the company’s operational updates, product milestones, financial disclosures, and restructuring process over time.
BIOLASE, Inc. (NASDAQ: BIOL) announced its schedule for investor conferences in September 2021. Key events include one-on-one meetings at the Colliers 2021 Institutional Conference on September 9 and a formal presentation at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, with the presentation available on September 13 at 7:00 am ET. The company's leadership, including CEO John Beaver and VP of Finance Jennifer Bright, will participate in virtual meetings with institutional investors. More details can be found on BIOLASE's investor relations website.
BIOLASE (NASDAQ: BIOL) announced a clinical advisory partnership with Dr. L. Stephen Buchanan to promote the adoption of laser technology in endodontics. This collaboration aims to enhance hands-on training programs, leveraging Dr. Buchanan's extensive experience in endodontics. Dr. Buchanan praised BIOLASE's Er,Cr:YSGG Waterlase device for its effectiveness in single-visit root canal treatments. The partnership is expected to advance laser technology in endodontic practices, benefiting both professionals and patients.
BIOLASE, Inc. (NASDAQ: BIOL) has appointed three new board members: Dr. Kathleen T. O'Loughlin, Dr. Carol Gomez Summerhays, and Dr. Martha Somerman, effective immediately. These appointments aim to enhance the Board's capabilities as the company pursues an aggressive growth strategy in the dental laser market. O'Loughlin brings experience from the American Dental Association, Summerhays is a former ADA president, and Somerman has a history with NIH. The Board now consists of nine members. Previous members Dr. Michael DiTolla and Garrett Sato resigned to pursue other interests.
BIOLASE, Inc. (NASDAQ: BIOL) reported a robust second quarter of 2021, with net revenue soaring 211% to $9.1 million, significantly exceeding pre-pandemic levels. U.S. and international laser sales surged 299% and 806%, respectively, reflecting increased dental procedures post-COVID-19. Gross margin improved to 44%, up 1,200 basis points year-over-year. The net loss narrowed to $702,000 from $4.7 million a year earlier, aided by a $3 million PPP loan forgiveness. Looking ahead, BIOLASE anticipates significantly higher third-quarter revenue than the prior year, driven by sustained demand for dental lasers.
BIOLASE, a leader in dental lasers, will announce its second quarter 2021 financial results on August 12, 2021. The results will be released after the U.S. market close, followed by a conference call at 4:30 p.m. ET. U.S./Canada participants can join by calling (800) 367-2403, while international participants can call (334) 777-6978, using Conference ID 9019839. An audio archive of the conference will be available for 30 days on the BIOLASE website.
BIOLASE, Inc. (NASDAQ: BIOL) announced that recent studies published in the International Journal of Periodontics & Restorative Dentistry and Lasers in Medical Science highlight the effectiveness of its Waterlase Er,Cr:YSGG laser technology in treating peri-implantitis. Led by Dr. Myron Nevins, the research indicates that the technology aids in debridement of titanium implant surfaces, enhancing regenerative treatment. Additional findings show significant reductions in bacteria on zirconia discs when treated with the laser, suggesting its growing relevance as a viable dental treatment option.
BIOLASE, a leader in dental lasers, announced its participation in the Summer Solstice Best Ideas from the Buy Side Conference from June 1-4, 2021. President and CEO John Beaver will present on June 2 at 9:00 am PT and conduct one-on-one meetings with institutional investors throughout the event. Investors can access a live audio webcast of the presentation via the provided link or through BIOLASE's investor relations website. The company specializes in laser systems for dentistry and medicine, with over 41,200 laser systems sold globally, demonstrating its market leadership.
BIOLASE, Inc. (NASDAQ: BIOL) partnered with Healthy Smiles For Kids of Orange County to conduct a pediatric dental laser training on May 8, enhancing the skills of dental professionals in pediatric procedures using Waterlase technology. This initiative aims to improve pediatric dental care as more patients return post-COVID-19. The training covered laser safety and techniques to deliver less painful dental experiences. The event is part of BIOLASE's efforts to support pediatric dentists and comes after the launch of their Waterlase Pediatric Dental Academy, which offers ongoing training and mentorship.
BIOLASE, Inc. (NASDAQ: BIOL) reported a strong first quarter for 2021, with net revenue rising 70% to $8.1 million, largely driven by a 139% increase in laser system sales. U.S. revenue surged 67%, while international revenue grew 75%. The gross margin improved to 34%, up 500 basis points year-over-year. Despite an operating loss of $6.1 million, the company maintains a robust balance sheet with $40.8 million in cash. BIOLASE anticipates significant revenue growth for the second quarter, forecasting between $7.5 million to $8.5 million, marking a year-over-year increase of 155% to 190%.
BIOLASE, a leader in dental lasers, announced it will release its first quarter 2021 financial results on May 13, 2021, after market close. A conference call will follow at 4:30 p.m. ET for discussing results and corporate developments. The call can be accessed via dial-in numbers for U.S./Canada and international participants. BIOLASE's laser systems enhance dental procedures, with over 41,200 systems sold in more than 80 countries. An audio archive will be available for 30 days post-call.
FAQ
What is the current stock price of BIOLASE (BIOL)?
What is the market cap of BIOLASE (BIOL)?
